CME Part I: Immune checkpoint inhibitors to treat cutaneous malignancies

As the incidence of cutaneous malignancies continues to rise and their treatment with immunotherapy expands, dermatologists and their patients are more likely to encounter these agents. While blockade of immune checkpoint target proteins (CTLA-4, PD-1, PD-L1) generates an antitumor response in a sub...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Am Acad Dermatol
Asıl Yazarlar: Barrios, Dulce M., Do, Mytrang H., Phillips, Gregory S., Postow, Michael A., Akaike, Tomoko, Nghiem, Paul, Lacouture, Mario E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7572574/
https://ncbi.nlm.nih.gov/pubmed/32461079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaad.2020.03.131
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller